• Novo Holdings co-led Breye Therapeutics’ EUR 67.5 million oversubscribed Series A with Mission BioCapital.
• Breye is a clinical-stage biopharmaceutical company developing oral treatments for early retinal diseases.
• Proceeds earmarked to move lead asset danegaptide into a randomized Phase II trial in non-proliferative diabetic retinopathy starting in 2027.
• Funding also supports pipeline work in retinal diseases, including an oral P2X7 receptor antagonist program for intermediate age-related macular degeneration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Holdings A/S published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.